Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

D S Alberts; P Y Liu; S P Wilczynski; A Jang; J Moon; J H Ward; J T Beck; M Clouser; M Markman

doi:10.1111/j.1525-1438.2007.00882.x

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

Identifier:nobleid.org/w1/20260515/CD18C409

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/CD18C409.svg?ark=w1%2F20260515%2FCD18C409)](https://nobleid.org/work/w1/20260515/CD18C409)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

Identifier:nobleid.org/w1/20260515/CD18C409

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/CD18C409.svg?ark=w1%2F20260515%2FCD18C409)](https://nobleid.org/work/w1/20260515/CD18C409)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work